Danny Boyle Reveals SUNSHINE Was Originally Meant to Be a Trilogy — GeekTyrant
It turns out the Danny Boyle-directed Sunshine wasn't just a one-way mission to reignite the dying sun, it was almost the start of a much bigger journey.
In a recent interview with Collider, Boyle dropped a bit of info for fans of his 2007 cult classic. While the film has found love over the years, bolstered by a stacked cast (Cillian Murphy, Michelle Yeoh, Chris Evans, Benedict Wong), it didn't exactly set the box office on fire when it first hit theaters, and that, unfortunately, may have cost us a full-blown trilogy.
Boyle said, referring to screenwriter and frequent collaborator Alex Garland:
'Originally, when we were doing it, Alex wrote two other parts. It was supposed to be a trilogy. It wasn't two other scripts; he had an outline for where the story would go.'
It wasn't just more sun-scorched tension or another twist on psychological sci-fi horror. Boyle teased:
'It was a planetary trilogy. It was to do with the sun itself, with two other stories.'
While he didn't go into too much detail, likely out of deference to Garland, he hinted at some pretty ambitious territory:
'What's interesting is Alex has a natural instinct as a storyteller to want to tell these expanding stories, and that is why 28 Years Later wound up as a trilogy.
'An extraordinary idea on kind of Elon Musk scale, even though he's lost a lot of credibility. But it was interplanetary stuff, it had more to do with that … there's no rich man in it. But the idea of looking outside and moving.'
He didn't spill anymore info, just in case Garland ever wants to revisit or repurpose those ideas. But, it's hard not to imagine what could've been… a trilogy about humanity's push into deep space, built around science, sacrifice, and sun-soaked dread.
Given that 28 Years Later is finally becoming a trilogy decades after 28 Days Later , maybe Sunshine isn't completely out of orbit just yet. Boyle has a knack for returning to stories that deserve a second (or third) shot. And if Garland's blueprints are still lying around somewhere, who knows? May it could happen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million from existing specialist investors, including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Paris, France – June 12, 2025Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial. New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in the round, of which $5 million will be allocated to Enterome upon closing and an additional $4 million in conditional tranched funding. Existing shareholders invested an additional $10 million including: SymBiosis, a U.S. venture capital firm; Seventure Partners, based in France; Lundbeckfonden BioCapital from Denmark; Primo Capital, an Italian venture capital and private equity firm; and The U.S. Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). 'Attracting highly specialized blood cancer investor IFLI to this financing demonstrates the conviction of our new and existing investors in the potential of OncoMimics™ for blood and solid tumor cancers,' said Pierre Bélichard, Enterome's Chief Executive Officer. 'We currently are generating exciting clinical proof of concept data for EO2463 monotherapy in several iNHL patient populations included in the Phase 1/2 SIDNEY clinical trial. Most importantly, EO2463 has shown robust clinical efficacy and exceptional safety and tolerability – which is especially impressive for such a potent immunotherapy. This offers a new hope for these patients and a rare opportunity to create an entirely new market segment for an impactful therapeutic. This financing will enable us to continue the SIDNEY trial of EO2463 and prepare to launch a first pivotal Phase 3 trial of this candidate for the 'watch-and-wait' iNHL population.' The company presented interim SIDNEY dataat the American Society of Hematology (ASH) conference in December 2024, showing highly encouraging responses in the Cohort 2 of 'watch and wait' iNHL patients in the ongoing SIDNEY study. This population, as the name suggests, is generally not eligible to receive other treatments due to the unacceptable risk-benefit ratio (in this iNHL sub-population) of the most commonly used blood cancer therapies. The company also recently disclosed having held positive meetings with both FDA (Type C meeting) and EMA (Scientific Advice), outlining a clear regulatory path registration for marketing authorizations in 'watch-and-wait' iNHL. 'This investment aligns with IFLI's mission to accelerate the development of innovative therapies and precision biomarkers for follicular lymphoma,' said Michel Azoulay, MD, Chief Medical Officer at IFLI. 'EO2463 represents a novel class of synthetic, off-the-shelf Immunotherapeutics with a unique mechanism of action that selectively targets malignant B cells. We are particularly interested in supporting Enterome's efforts to demonstrate EO2463's clinical efficacy across multiple lines of therapy, including in relapsed and refractory settings.' Enterome recently announced that it will present new data showing EO2463 also has a meaningful impact when tested in combination with standard of care in relapsed and refractory iNHL patients at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21. Previous findings presented at ASCO in 2024 in the relapsed and refractory patient population further suggested the potential to identify individuals most likely to benefit from EO2463 treatment, supported by biomarker analyses. Lore Gruenbaum, Chief Scientific Officer at LLS, said, 'It is important for us to continue to support Enterome, a company working to develop novel therapeutics based on our shared commitment to create better therapies for blood cancers. LLS has invested over $1.8 billion in groundbreaking research since our inception in 1949. Our active partnership with Enterome, through our Therapy Acceleration Program, will continue to advance the clinical development of the OncoMimics™ family of novel immunotherapeutics for the benefit of blood cancer patients. We are particularly excited to help advance EO2463 which has shown promising signs of efficacy as monotherapy with excellent safety and tolerability in 'watch-and-wait' iNHL patients, who currently have no approved treatment options.' EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimics™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that mimic the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells' capacity to develop immune-resistance mechanisms such as antigen escape. SIDNEY is an ongoing 12-month open label Phase 1/2 study that aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in up to about 55 patients with follicular lymphoma and marginal zone lymphoma including divided into three cohorts: newly diagnosed patients eligible to watch-and-wait (monotherapy); newly diagnosed patients in need of therapy / first line (combo with rituximab); patients with relapsed/refractory disease (combo with R2). In addition to safety, survival, response rates and other measures of efficacy are being collected. OncoMimics™ were inspired by the microbial origin of certain autoimmune diseases. The Company uses AI and machine learning to identify microbial proteins that closely mimic the structure, effect or actions of specific cancer antigens (as well as hormones or cytokines). Memory T cells against microbial antigen are created during early development, sometimes leading to autoimmune disorders. In the case of OncoMimics™, however, this means that the immune system can mount a rapid, robust and durable immune response that is highly targeted and specific for the OncoMimics™ and the cancer antigens they closely resemble. This is possible because, unlike cancer antigens, OncoMimics™ bypass the biological process, known as thymic deletion, that prevents the immune system from mounting an attack against the 'self' proteins (e.g. antigen) on tumor and blood cancer cells. Once activated, the immune system attacks with high specificity and potency the cancer antigens targeted by the OncoMimics™, killing the cancer cells that carry them. OncoMimics™ are synthetic peptides that are easy to manufacture, store, distribute and administer as an off-the-shelf subcutaneous injection. In clinical testing to date they have been shown to be extremely well tolerated, especially compared to other potent immunotherapies. Enterome SA ( is a privately held clinical-stage biopharmaceutical company developing OncoMimics™, a new proprietary immunotherapeutic modality inspired by the microbial origin of certain autoimmune diseases, to treat cancer. The Company's wholly-owned OncoMimics™ pipeline includes three distinct clinical-stage drug candidates: EO2463 to treat indolent non-Hodgkin lymphomas; EO4010 to treat third-line colorectal cancer; and EO2401 to treat glioblastoma and adrenal tumors. Each of these candidates has shown positive early clinical efficacy and exceptional safety and tolerability. For more information, please contact: ENTEROME INVESTOR & MEDIA RELATIONS Pierre BélichardChief Executive Officer +33 (0)1 75 77 27 85 Cohesion BureauChris Maggos / Giovanni Ca' Zorzi +41 (0)79 367 6254 / +33 (0)7 84 67 07 27enterome@ Attachment 20250612_Enterome _PR_Funding_Round_finalError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
The Countdown Begins: Pre-Register Now for My Talking Tom Friends 2 by Outfit7
LIMASSOL, Cyprus , June 12, 2025 /PRNewswire/ -- The squad is back, and they're cooler than ever! Outfit7 is setting the stage for a bold new chapter in the Talking Tom & Friends franchise with My Talking Tom Friends 2 – the highly anticipated sequel to the global hit that captured millions of hearts worldwide. With a fresh visual style, expanded gameplay, and deeper character connections, fans can now pre-register to be among the first to experience this exciting new story and unlock the exclusive Rizzler outfit at launch. Building on the success of the 2020 original – which has over 1.7 billion downloads – My Talking Tom Friends 2 amps up the fun and friendship like never before. Players can dive deeper into the lives of Talking Tom, Angela, Hank, Ben, and Becca with richer interactions and playful surprises at every turn. Whether exploring the new neighborhood, hanging out in their individual homes, or teaming up in fresh mini-games, players will create unforgettable memories with their favorite crew. What's New in My Talking Tom Friends 2? A Fully Interactive Neighborhood – Vibrant new locations and hidden surprises. Individual Homes – Each friend now has their own space, reflecting their unique personality and style. Mini-Games, Big Fun – Race, paint, craft, score goals, and more with a variety of fresh challenges. Speaking with Real Voices – Hear the characters come alive through real jokes, reactions, and Beyond the Neighborhood – Enjoy special trips to new worlds packed with surprises. Don't miss out – Pre-register now and unlock your exclusive Rizzler outfit at launch. Your new neighborhood adventure awaits! Note: Pre-registration promotion is subject to the terms available at ABOUT MY TALKING TOM FRIENDS 2:Developed by Outfit7 Limited, My Talking Tom Friends 2 takes virtual pet gameplay to the next level in an interactive neighborhood where players can explore, play, and create their own stories. Join Talking Tom, Angela, Becca, Hank, and Ben-now teenagers-as they embark on exciting adventures through fun locations like the arcade, water park, and science center. Customize homes, enjoy immersive activities, and experience real spoken dialogue. My Talking Tom Friends 2 offers endless entertainment for players of all ages. Discover more HERE. Photo: Contact: media@ View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
We can cure baldness, claim scientists
Anxiously checking in the mirror for signs of male pattern baldness may be a thing of the past, as scientists in Madrid believe they have found a way to reverse hair loss. Researchers at the San Carlos clinic in the Spanish capital claim they were able to regrow hair on mice in almost all cases during an experimental stem cell treatment study. The project involved giving male and female mice dihydrotestosterone, a by-product of testosterone that causes receding hair lines in men and thinning hair in women. Once the rodents had lost all their fur, half of them were injected with stem cells taken from body fat as well as a chemical called adenosine triphosphate, which stimulates cellular growth. The other half were given a placebo. All the male mice given the stem cell-chemical cocktail experienced hair regrowth, with around half getting back all their fur. The majority of the female mice also regrew their coats. 'Hair grew back in all of the treated male mice. In the case of the females, a lower dose was used, and the results were also somewhat worse, although still good, because 90 per cent managed to repopulate their hair,' Dr Eduardo López Bran, head of dermatology at the San Carlos, explained. The scientists, whose work was published in Stem Cell Research & Therapy, say that it will still be four or five years before a drug could be available, and that the next phase of testing will involve using human patients. Hair loss or alopecia is a common complaint in Spain, which has the highest percentage of bald men in the world at 44.5 per cent, according to a survey by Medihair, an online platform for hair loss treatments. Dr López Bran said he had 'noticed a huge increase in inquiries seeking a solution, a truly significant growth in demand, especially among young people who, at the first signs of baldness, want to slow its progression, or even reverse those initial symptoms'. By the age of 50, roughly 50 per cent of men will experience some form of male pattern baldness. Around 25 per cent of will spot signs of thinning or receding as early as 21. Hair transplant surgery has become increasingly popular over the last two decades, with the number of procedures performed globally rising by 76 per cent since 2006. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
